Rodney JY Ho, UW professor in pharmaceutics and adjunct professor in bioengineering, has been elected as a fellow of the National Academy of Inventors, a prestigious distinction that recognizes and honors the creators or co-developers of outstanding inventions that have made a difference in society.
His research focuses on innovations in drug formulations and systems approaches to drug targeting and long-acting therapy, particularly for cancer and viral infectious diseases. His research has led to enhanced HIV, cancer and pain medication potency and safety.
Dr. Ho is executive director of Washington Entrepreneurial Research Evaluation and Commercialization Hub (WE-REACH). He is also founder and director of the Targeted Long-acting Combination Anti-Retroviral Therapeutic (TLC-ART) program, which works to identify the most effective HIV treatments for adults and children.
“I am honored to be elected as a fellow of the National Academy of Innovators and cited for translating biomedical innovations into products making an impact on the quality of life,” Dr. Ho told the UW School of Pharmacy.
Dr. Ho will be formally inducted at the NAI Fellows Induction Ceremony during the organization’s annual meeting June 7-9, 2021, in Tampa, Fla.
WE-REACH Executive Director Dr. Rodney JY Ho to be named NAI Fellow